Elotuzumab Safety Surveillance In Japanese Patients With Relapse Or Refractory Multiple Myeloma

Bristol-Myers Squibb (BMS)

Status: Completed

Conditions: Multiple Myeloma

Treatments: Other: No Intervention

Study type: Observational

Funder types: Industry

Identifiers

NCT02976493

CA204-179

Details and patient eligibility

About

BMS will conduct a regulatory postmarketing surveillance (PMS) to evaluate the safety of elotuzumab in clinical practice in Japan.

Enrollment: 500 patients

Sex: All

Volunteers: No Healthy Volunteers

Inclusion criteria

• All patients with relapsed or refractory multiple myeloma who are beginning to receive elotuzumab at the selected sites will be included in this surveillance study

Exclusion criteria

• Not Applicable

Trial design

500 participants in 1 patient group

MM patients receiving elotuzumab

Description:

Non-Interventional Study of all patients with relapsed or refractory multiple myeloma (MM) who are beginning to receive elotuzumab at the selected sites.

Treatment:

Other: No Intervention